Felix Chua

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1362695/publications.pdf

Version: 2024-02-01

26 papers	1,196 citations	516710 16 h-index	552781 26 g-index
30 all docs	30 docs citations	30 times ranked	1882 citing authors

#	Article	IF	Citations
1	Delays in idiopathic pulmonary fibrosis diagnosis and treatment: Time for change. Respirology, 2022, 27, 10-11.	2.3	1
2	Shortâ€term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis. Respirology, 2022, 27, 202-208.	2.3	11
3	CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1440-1448.	5.6	14
4	The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 339-347.	5.6	45
5	Serum markers of pulmonary epithelial damage in systemic sclerosisâ€associated interstitial lung disease and disease progression. Respirology, 2021, 26, 461-468.	2.3	30
6	BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 136-139.	5.6	15
7	Early prognostication of COVID-19 to guide hospitalisation versus outpatient monitoring using a point-of-test risk prediction score. Thorax, 2021, 76, 696-703.	5.6	24
8	Retrospective caseâ€“control study to evaluate hypocalcaemia as a distinguishing feature of COVID-19 compared with other infective pneumonias and its association with disease severity. BMJ Open, 2021, 11, e053810.	1.9	7
9	Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. European Respiratory Journal, 2020, 55, 1901681.	6.7	11
10	Transbronchial cryobiopsy for diagnosis of pleuroparenchymal fibroelastosis. Respiratory Medicine Case Reports, 2020, 31, 101164.	0.4	2
11	Mixed Ventilatory Defects in Pulmonary Sarcoidosis. Chest, 2020, 158, 2007-2014.	0.8	28
12	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	12.1	28
13	The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. Lancet Respiratory Medicine,the, 2020, 8, 438-440.	10.7	74
14	Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent. European Respiratory Journal, 2020, 55, 1901519.	6.7	42
15	Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. European Respiratory Journal, 2020, 56, 1902135.	6.7	34
16	Images of the month 1: Cough before the storm: A case of pulmonary alveolar microlithiasis. Clinical Medicine, 2020, 20, 110-111.	1.9	2
17	Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics. Annals of the American Thoracic Society, 2019, 16, 1351-1359.	3.2	110
18	The potential impact of azithromycin in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800628.	6.7	32

#	Article	IF	Citations
19	Clinical utility of existing and second-generation interferon-Î³ release assays for diagnostic evaluation of tuberculosis: an observational cohort study. Lancet Infectious Diseases, The, 2019, 19, 193-202.	9.1	47
20	Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Research, 2018, 4, 00049-2018.	2.6	24
21	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 759-770.	10.7	145
22	Pleuroparenchymal Fibroelastosis. American Journal of Surgical Pathology, 2017, 41, 1683-1689.	3.7	57
23	An emerging interstitial lung disease. Lancet Respiratory Medicine,the, 2016, 4, 762.	10.7	2
24	Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted. Respiratory Medicine, 2016, 120, 131-133.	2.9	8
25	Mice Lacking Neutrophil Elastase Are Resistant to Bleomycin-Induced Pulmonary Fibrosis. American Journal of Pathology, 2007, 170, 65-74.	3.8	130
26	Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 9-13.	2.9	268